Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
Genentech, 29 Jun 2015
Accessed on 30 Jun 2015 from http://www.gene.com/media/press-releases/14597/2015-06-29/genentechs-ocrelizumab-significantly-red.
